Acrobiosystems Co

Acrobiosystems Co Equity

The The Equity of Acrobiosystems Co (301080.SZ) as of Nov 16, 2026 is 2.66 B CNY. In the previous year, The Equity was 2.62 B CNY — a change of 1.61% (higher).

Equity

2.66 BCNY

YoY

1.61%

Last updated:

In 2025, Acrobiosystems Co's equity was 2.66 B CNY, a 1.61% increase from the 2.62 B CNY equity in the previous year.

The Acrobiosystems Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
73.31 M CNY
Jan 1, 2019
97.39 M CNY
Jan 1, 2020
200.30 M CNY
Jan 1, 2021
2.47 B CNY
Jan 1, 2022
2.56 B CNY
Jan 1, 2023
2.59 B CNY
Jan 1, 2024
2.62 B CNY
Jan 1, 2025
2.66 B CNY
The Acrobiosystems Co Equity history
YEAREquityYoY
2.66 BCNY+1.61%
2.62 BCNY+1.01%
2.59 BCNY+1.03%
2.56 BCNY+3.90%
2.47 BCNY+1,131.61%
200.30 MCNY+105.67%
97.39 MCNY+32.85%
73.31 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Acrobiosystems Co's Equity

Acrobiosystems Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Acrobiosystems Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Acrobiosystems Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Acrobiosystems Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Acrobiosystems Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Acrobiosystems Co stock

The Equity of Acrobiosystems Co is 2.66 B CNY in 2025.

The Equity of Acrobiosystems Co changed from 2.62 B CNY to 2.66 B CNY, representing a 1.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co